Payment overview · 2025
General Payments
$94.81
4 reported records · 4 companies
Healthcare provider profile · identity verified
Daniel Hilton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTINGTON BEACH, CA · NPI 1093811358
Verified facts
What the public records show
CMS Open Payments records show Daniel Hilton, MD received $94.81 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.90 | 34.7% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $22.19 | 23.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.92 | 23.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.80 | 18.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.81 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| CLARIFIX Normalized: clarifix |
Device | Stryker Corporation | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 109 |
| Famotidine | Famotidine | 272 | 103 |
| Eliquis | Apixaban | 257 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 108 |
| Fluticasone Propionate | Fluticasone Propionate | 206 | 100 |
| Furosemide | Furosemide | 178 | 75 |
| Lisinopril | Lisinopril | 178 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 40 |
| Metformin Hcl | Metformin Hcl | 146 | 46 |
| Lactulose | Lactulose | 137 | 46 |
| Levofloxacin | Levofloxacin | 125 | 116 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 117 | 36 |
| Omeprazole | Omeprazole | 116 | 23 |
| Gabapentin | Gabapentin | 115 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 43 |
| Losartan Potassium | Losartan Potassium | 105 | 41 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 100 | 19 |
| Montelukast Sodium | Montelukast Sodium | 99 | 17 |
| Carvedilol | Carvedilol | 96 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 29 |
| Sodium Chloride | 0.9 % Sodium Chloride | 85 | 28 |
| Cephalexin | Cephalexin | 84 | 73 |
| Prednisone | Prednisone | 84 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 24 |
| Budesonide | Budesonide | 80 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 68 |
| Tramadol Hcl | Tramadol Hcl | 73 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 26 |
| Azithromycin | Azithromycin | 69 | 50 |
| Simvastatin | Simvastatin | 69 | 17 |
| Donepezil Hcl | Donepezil Hcl | 66 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 62 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 19 |
| Humalog | Insulin Lispro | 61 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 15 |
| Midodrine Hcl | Midodrine Hcl | 60 | 36 |
| Levetiracetam | Levetiracetam | 57 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 16 |
| Sucralfate | Sucralfate | 53 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 31 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Creon | Lipase/Protease/Amylase | 43 | suppressed |
| Latanoprost | Latanoprost | 43 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 43 | 35 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 17 |
| Finasteride | Finasteride | 40 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 11 |
| Linzess | Linaclotide | 38 | suppressed |
| Metronidazole | Metronidazole | 38 | 36 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 17 |
| Spironolactone | Spironolactone | 34 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | 16 |
| Naloxone Hcl | Naloxone Hcl | 33 | 18 |
| Santyl | Collagenase Clostridium Hist. | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 13 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 17 |
| Glipizide | Glipizide | 29 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Admelog | Insulin Lispro | 28 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | 11 |
| Nystatin | Nystatin | 25 | 19 |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Glucagon Emergency Kit | Glucagon | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 24 | 15 |
| Alprazolam | Alprazolam | 23 | suppressed |
| Constulose | Lactulose | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Glucagon Emergency Kit | Glucagon Hcl | 21 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 21 | 11 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 20 | 12 |
| Allopurinol | Allopurinol | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Permethrin | Permethrin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Meropenem | Meropenem | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.81 · 4 records | ABBVIE INC. | CLARIFIX, NUZYRA, Tymlos, VRAYLAR, XHANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error